An Algerian Family with TNF Receptor Associated Periodic Syndrome (TRAPS) Associated Amyloidosis and the p.Thr79Met Mutation

Ghalia Khellaf1*, Messaoud Saidani1, Tahar Rayane2, Louiza Kaci3, Emmanuel Khalifa4, Serge Amselem5, Gilles Grateau6, Djoher Ait idir6,7, and Mohamed Benabadj1

1Department of Nephrology, University of Algiers Benkhedha Youssef, Beni Messous Hospital, Algeria
2Department of Nephrology, University of Algiers Benkhedha Youssef, Neffissa Hamoud Hospital, Algeria
3Pathology Private Laboratory, Algeria
4Department of Molecular Genetics, Sorbonne University, Armand Trousseau Hospital, Paris, France
5Department of Internal Medicine, Sorbonne University, Tenon Hospital, Paris, France
6Faculty of Biological Sciences, University of Science and Technology - Houari Boumediene, Algeria
7Faculty of Sciences, M'Hamed Bouguerra University, Boumerdes, Algeria

Corresponding author: Ghalia Khellaf, Department of Nephrology, University of Algiers Benkhedha Youssef, Beni Messous Hospital, Algeria, Tel: 0773641197; E-mail: g.khellaf@yahoo.fr

Received Date: June 18, 2018; Accepted Date: July 09, 2018; Published Date: July 12, 2018

Abstract

We report the case of a 36-year-old woman of Algerian descent on dialysis for renal AA amyloidosis. She reported since the age of 6 years recurrent episodes of 2 weeks duration characterized by fever, weakness, abdominal pain, myalgias, arthralgias, erythema, and chest pain. Diagnosis of TRAPS was confirmed by the presence of heterozygous p.Thr79Met mutation in TNFRSF1A. Genetic evaluation of all affected members of her family disclosed the p.Thr79Met mutation in TNFRSF1A, including one patient with amyloidosis. Genotype-phenotype correlations revealed variable clinical presentation and incomplete penetrance. TRAPS is a rare Mendelian auto-inflammatory disease that may be observed in populations where familial Mediterranean fever is highly prevalent. In this context, a high level of clinical suspicion is mandatory to evoke the diagnosis of TRAPS and initiate the appropriate treatment in order to prevent AA amyloidosis and its renal consequences.

Keywords: TRAPS; Algeria; FMF; AA Amyloidosis

Abbreviations

CRP: C-Reactive Protein; FMF: Familial Mediterranean Fever; IL: Interleukin; MEVF: Mediterranean Fever; SAA: Serum Amyloid A Protein; TNFRSF1A: (TNF) Tumor Necrosis Factor Receptor Super Family 1A; TRAPS: (TNF) Receptor Associated Periodic Syndrome

Introduction

TNF Receptor Associated Periodic Syndrome (TRAPS) is characterized by recurrent attacks of fever associated with abdominal pain, myalgias, migratory erythematous skin rash, conjunctivitis, and periorbital edema [1]. In contrast to patients with familial Mediterranean fever (FMF), patients with TRAPS usually have a poor response to colchicine, but a favourable response to corticosteroids and to interleukin (IL)-1 inhibitors. TRAPS has been described mostly in families of north European descent. The most thoroughly characterized was a large pedigree of Irish and Scottish ancestry ascertained in Nottingham, England, whose illness was denoted familial Hibernian fever [2]. TRAPS is a very rare disease with an estimated prevalence of about one per million [3]. It has rarely been reported in Arabic population, where FMF is in contrast highly prevalent. We report the first cases of TRAPS complicated by amyloidosis in a family from the south of Algeria, which has been diagnosed late in the course of the disease.

Case Description

The proband (II/7 Figure 1) is a 36-year-old woman native of southern Algeria. Her parents were first cousins. She was hospitalized in February 2013 for kidney biopsy in front of nephrotic syndrome and renal insufficiency (creatinine clearance at 45 mL/min). She has a history of recurrent inflammatory attacks since the age of 6 years. These attacks are characterized by fever of more than 15 days and fasciitis affecting the limbs with a typical migrating proximal to acral evolutive pattern during the attack. Other symptoms during attacks are abdominal pain first localized then diffuse at the acme of the fever, arthralgias with no signs of arthritis, headache, periorbital edema, and fatigue. She underwent an appendicectomy at the age of 10 that did not suppress recurrent abdominal attacks. Some attacks were triggered by physical stress and menstruation. At the age of 35 years, the patient presented with a major edematous syndrome and orthostatic hypotension, proteinuria at 3 g/day and hypoalbuminemia at 14 g/L.
Inflammation was present with C-reactive protein (CRP) at 120 mg/L and anemia (hemoglobin 9 g/dL). Immunological workup was unremarkable for autoimmune diseases (normal complement, C3, C4, negative anti-nuclear antibodies, anti-DNA and anti-neutrophil cytoplasm antibodies), while serum protein electrophoresis and immunofixation excluded gammopathies. Kidney biopsy disclosed AA amyloidosis (Figure 2).

Finally genetic study was done after informed consent obtained from the patient and all of her family (Figure 1) that showed no mutation in the MEVF gene and disclosed the p.Thr79Met (formerly T50M) mutation in the TNFRSF1A gene at the heterozygote state. Since August 2013, the patient has been on chronic hemodialysis with many complications: hypotension, recurrent thrombosis of the fistula. Attacks are less frequent, spaced with one each six months, but remain very painful especially when fasciitis occurs on the side of the fistula with hyperleukocytosis, thrombocytosis and CRP at 130 mg/L. Attacks remain responsive to intravenous corticosteroid therapy. Amyloidosis is still evolutive as the patient has developed a probable amyloid goitre.

Her father, (Patient I/2 Figure 1) aged 70 years is on hemodialysis since the age of 52 for chronic renal disease of undetermined cause. He had a long history of recurrent attacks since the age of 12 years with approximately 3 attacks per year. Attacks last 15 days with fever, fasciitis, arthralgias, abdominal pain, unilateral scrotitis, periorbital edema. Edematous syndrome appeared at the age of 38 years and hemodialysis was started at the age of 40. Since he has been on hemodialysis, the patient has remained free of clinical inflammatory attacks; fistula performed at the left radial artery 30 years ago is still functional. He has developed a euthyroid goiter, and his CRP remains normal. Salivary gland biopsy returned in favor of AA amyloidosis (Figure 3).
inflammatory attacks of fever, arthralgias, and skin lesions. The patient had several hospitalizations in pediatric wards and the diagnosis of untagged rheumatism was made and symptomatic treatment was started. She was depressed because of prolonged bed rest. In 2014 she had hemoglobin at 10 g/dL, a CRP at 20 mg/l and no renal disease. Salivary gland showed no amyloid deposits. She was first treated with colchicine at 2 mg/day without clinical or biological benefit and after genetic results with prednisone at 10 mg/day. She is since clinically asymptomatic with a CRP at 10 mg/L. Both this patient and her father harbor the p.Thr79Met mutation of the TNFRSF1A gene.

Discussion

We report a TRAPS family native to the south of Algeria. Clinical presentation is quite typical of TRAPS phenotype with quarterly or even semi-annual inflammatory attacks of 15 to 21 days. Symptoms observed during attacks are: migratory fasciitis, arthralgias of large joints, abdominal pain simulating a surgical emergency, unilateral vaginitis, with a frank acute phase response, all spontaneously resolving in 15 to 28 days [4-6]. The p.Thr59Met mutation found in this family has already been described in TRAPS patients belonging to other populations [1]. Moreover, in our family, it segregates with the disease as all clinically affected individuals over 3 generations harbour the mutation. However, two individuals harbour this mutation and remain currently free of clinical symptoms, thus conveying the incomplete penetrance of the mutation in this family. Clinical expression is relatively similar in all patients except for amyloidosis that occurred in two of them and at a young age in the proband. Amyloidosis is usually associated with mutations involving cysteine residues that confer the most severe phenotype in TRAPS. However, amyloidosis has already been reported with p.Thr59Met [5,6]. These two characteristics: incomplete penetrance and variable expression of the disease including the presence of amyloidosis have widely been described in TRAPS [5,7].

The p.Thr79Met mutation of the TNFRSF1A gene is one of the most frequent associated with TRAPS. It has been described in a number of families, mainly of European ancestry [1]. To our knowledge it has not been described in patients of Algerian origin. Several cases of TRAPS patients have already been reported among the Arab population from the Middle East (Iraq, Kuwait) and Maghreb (Mauritania) and in Africans too, with other mutations (p.Thr66Ile, p.Cys72Tyr, p.Thr79Lys) [8].

We wish to emphasize the delayed diagnosis of TRAPS in this family. Indeed, in the settings of a history of recurrent inflammatory attacks and amyloidosis in a family belonging to a population where FMF is frequent, this latter diagnosis was suspected and colchicine was started. She was depressed because of prolonged bed rest. In 2014 she had hemoglobin at 10 g/dL, a CRP at 20 mg/l and no renal disease. Salivary gland showed no amyloid deposits. She was first treated with colchicine at 2 mg/day without clinical or biological benefit and after genetic results with prednisone at 10 mg/day. She is since clinically asymptomatic with a CRP at 10 mg/L. Both this patient and her father harbor the p.Thr79Met mutation of the TNFRSF1A gene.

Conclusion

This family from southern Algeria has a long history of diagnostic wandering. The strong consanguinity in this family is a deceptive
element since it reinforced the hypothesis of a recessive disease led to the wrong diagnosis of FMF and delayed the diagnosis of TRAPS. This emphasizes the importance of a precise analysis of the clinical symptoms in a context of recurrent familial fever in a country where FMF is highly prevalent as well as the interest of the negative therapeutic test with colchicine in this context. This case also highlights the value of the molecular diagnosis which led to a targeted therapeutic management.

Conflict of Interest

The authors have no conflict of interest to declare.

Consent Obtained

All patients and healthy family members gave written consent for genetic analysis and anonymous publication.

Ethical Approval for this Study

All the patients of this study have given writing consent formal consent is not required. This article does not contain any studies with humans or animals performed by any of the authors.

References